Xeno Biosciences, founded to address large unmet needs in metabolic diseases, is a biopharmaceutical company pioneering novel therapeutics. Their core mission is to develop transformational therapies for conditions like obesity, which have limited treatment options beyond bariatric surgery. The company's lead program, XEN-101, is a first-in-class oral formulation designed to shift the gut microbiome to a state associated with weight loss, mimicking the effects of Roux-en-Y gastric bypass surgery. Xeno Biosciences focuses on delivering innovative solutions to improve patient health and quality of life.

The company is led by an experienced team of professionals in the biopharmaceutical industry. Notable investors include prominent venture capital firms specializing in healthcare and biotechnology. Key achievements include advancing XEN-101 through clinical stages, demonstrating its potential to transform the treatment landscape for metabolic diseases. Xeno Biosciences' impact is significant, offering hope for effective, non-surgical interventions for obesity and related metabolic disorders.